Skip to main content

An official website of the United States government

You have 2 new alerts

Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products

Looking for contract opportunity help?

APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.

APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.

The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).

General Information

  • Contract Opportunity Type: Solicitation (Updated)
  • Updated Published Date: Jul 17, 2023 05:50 pm EDT
  • Original Published Date: Jun 20, 2023 10:01 pm EDT
  • Updated Date Offers Due: Aug 18, 2023 03:00 pm EDT
  • Original Date Offers Due: Aug 04, 2023 03:00 pm EDT
  • Inactive Policy: 15 days after date offers due
  • Updated Inactive Date: Sep 02, 2023
  • Original Inactive Date: Aug 19, 2023
  • Initiative:
    • None

Classification

  • Original Set Aside:
  • Product Service Code: AN12 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
  • NAICS Code:
    • 325412 - Pharmaceutical Preparation Manufacturing
  • Place of Performance:
    USA

Description

The Therapeutic Development Branch (TDB) within the Division of Preclinical Innovation (DPI) at the National Center for Advancing Translational Sciences (NCATS) conducts translational research in the area of human therapeutics development.

The scope of this contract is for Chemistry, Manufacturing, and Control (CMC) services for Drug Products. The objective of these support services is to ensure receipt of formulated Drug Product (DP) of sufficient quality and quantity to support preclinical,  IND-enabling and clinical studies. 

The Contractor shall provide support for a broad range of preclinical services required for the design, development, manufacture, and release of DP, and release of DP as Clinical Trial Material (CTM), including precursors, preliminary states, Reference Standards (RS) and all required testing. Ancillary products (e.g., placebos, diluents, adjuvants, master cell banks, testing standards, reference materials) and other materials manufactured or purchased to support clinical trials or CMC activities may also be required. All activities preliminary to manufacturing in accordance with current Good Manufacturing Practice (cGMP) may be required (e.g., development or engineering lots, formulation studies), even without an associated cGMP manufacturing task. All activities required to maintain material in a usable state, including storage, shipping, testing (in process, release, stability, and quality actions), and preparation of documents to support regulatory submissions may also be required.

Product formats may include small molecules, short oligomeric compounds, biological (large) molecules, quaternary molecular assemblies (homogenous or heterogenous), vectors for gene therapy, nanoparticles, and any  of the above modified genetically, biologically, or chemically. Novel formats  identified after this draft might also be needed. Formats could also include Devices or Combination Products.

The breadth of this Statement of Work (SOW) includes capabilities to support a range of activities differing in size, complexity, and duration.

All applicable attachments in connection with this solicitation are available for download.

Contact Information

Contracting Office Address

  • c/o 3WFN MSC 6012 301 N Stonestreet Ave
  • Bethesda , MD 20892
  • USA

Primary Point of Contact

Secondary Point of Contact

History